Peter K. S. Siegl

6.7k total citations · 1 hit paper
100 papers, 4.0k citations indexed

About

Peter K. S. Siegl is a scholar working on Molecular Biology, Cardiology and Cardiovascular Medicine and Organic Chemistry. According to data from OpenAlex, Peter K. S. Siegl has authored 100 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Molecular Biology, 47 papers in Cardiology and Cardiovascular Medicine and 21 papers in Organic Chemistry. Recurrent topics in Peter K. S. Siegl's work include Receptor Mechanisms and Signaling (34 papers), Cardiac electrophysiology and arrhythmias (20 papers) and Renin-Angiotensin System Studies (20 papers). Peter K. S. Siegl is often cited by papers focused on Receptor Mechanisms and Signaling (34 papers), Cardiac electrophysiology and arrhythmias (20 papers) and Renin-Angiotensin System Studies (20 papers). Peter K. S. Siegl collaborates with scholars based in United States, Germany and Austria. Peter K. S. Siegl's co-authors include Alice Davis, Russell Wallis, W. G. Lynch, Ian C. Mackenzie, Leif Carlsson, Michael C. Sanguinetti, Victor J. Lotti, Gregory J. Kaczorowski, Gloria J. Zingaro and Nancy K. Jurkiewicz and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Circulation.

In The Last Decade

Peter K. S. Siegl

99 papers receiving 3.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development

2003 1.2k citations Leif Carlsson, Alice Davis et al. Cardiovascular Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter K. S. Siegl United States	29	2.4k	2.3k	754	354	304	100	4.0k
Joseph J. Lynch United States	38	2.1k 0.9×	1.8k 0.8×	411 0.5×	637 1.8×	277 0.9×	165	4.3k
Hiroyuki Kobayashi Japan	36	422 0.2×	2.2k 1.0×	770 1.0×	306 0.9×	440 1.4×	220	5.0k
John Hwa United States	48	840 0.4×	3.6k 1.6×	1.5k 2.0×	115 0.3×	624 2.1×	130	6.6k
Huy Ong Canada	37	783 0.3×	2.0k 0.9×	387 0.5×	339 1.0×	580 1.9×	140	4.4k
Bernard Rubin United States	24	998 0.4×	2.0k 0.9×	833 1.1×	219 0.6×	326 1.1×	63	3.6k
Nicole Helbecque France	33	808 0.3×	1.2k 0.5×	182 0.2×	202 0.6×	793 2.6×	90	3.0k
P. Schelling Germany	28	1.1k 0.5×	968 0.4×	273 0.4×	102 0.3×	236 0.8×	69	2.4k
Michael K. Pugsley United States	27	1.2k 0.5×	1.1k 0.5×	455 0.6×	76 0.2×	192 0.6×	119	2.6k
Laurent Audoly United States	38	732 0.3×	1.8k 0.8×	377 0.5×	326 0.9×	691 2.3×	69	5.9k
Thomas G. Parker Canada	39	2.0k 0.8×	2.4k 1.0×	210 0.3×	77 0.2×	278 0.9×	113	4.6k

Countries citing papers authored by Peter K. S. Siegl

Since Specialization

Citations

This map shows the geographic impact of Peter K. S. Siegl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter K. S. Siegl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter K. S. Siegl more than expected).

Fields of papers citing papers by Peter K. S. Siegl

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter K. S. Siegl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter K. S. Siegl. The network helps show where Peter K. S. Siegl may publish in the future.

Co-authorship network of co-authors of Peter K. S. Siegl

This figure shows the co-authorship network connecting the top 25 collaborators of Peter K. S. Siegl. A scholar is included among the top collaborators of Peter K. S. Siegl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter K. S. Siegl. Peter K. S. Siegl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ferri, Nicola, Peter K. S. Siegl, Alberto Corsini, et al.. (2013). Drug attrition during pre-clinical and clinical development: Understanding and managing drug-induced cardiotoxicity. Pharmacology & Therapeutics. 138(3). 470–484. 139 indexed citations

Bass, Alan, Hugo M. Vargas, Jean‐Pierre Valentin, et al.. (2011). Safety pharmacology in 2010 and beyond: Survey of significant events of the past 10 years and a roadmap to the immediate-, intermediate- and long-term future in recognition of the tenth anniversary of the Safety Pharmacology Society. Journal of Pharmacological and Toxicological Methods. 64(1). 7–15. 8 indexed citations

Siegl, Peter K. S., et al.. (2010). Relevance of a standard food model in combination with electronic jaw movement recording on human mastication pattern analysis. Advances in Bioscience and Biotechnology. 1(2). 68–78. 2 indexed citations

Guth, Brian D., Richard J. Briscoe, Simon Chivers, et al.. (2009). Comparison of electrocardiographic analysis for risk of QT interval prolongation using safety pharmacology and toxicological studies. Journal of Pharmacological and Toxicological Methods. 60(2). 107–116. 41 indexed citations

Carlsson, Leif, Alice Davis, W. G. Lynch, et al.. (2003). Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovascular Research. 58(1). 32–45. 1186 indexed citations breakdown →

Ikeda, Takanori, Hisashi Ohta, Megumu Okada, et al.. (2000). Antihypertensive Effects of a Mixed Endothelin-A- and -B-Receptor Antagonist, J-104132, Were Augmented in the Presence of an AT1-Receptor Antagonist, MK-954. Journal of Cardiovascular Pharmacology. 36(Supplement 1). S337–S341. 16 indexed citations

Touzani, Omar, S Galbraith, Peter K. S. Siegl, & James McCulloch. (1997). Endothelin-B Receptors in Cerebral Resistance Arterioles and their Functional Significance after Focal Cerebral Ischemia in Cats. Journal of Cerebral Blood Flow & Metabolism. 17(11). 1157–1165. 27 indexed citations

Kivlighn, Salah D., Gloria J. Zingaro, Robert A. Gabel, et al.. (1995). In vivo pharmacology of an angiotensin AT1 receptor antagonist with balanced affinity for angiotensin AT2 receptors. European Journal of Pharmacology. 294(2-3). 439–450. 3 indexed citations

Siegl, Peter K. S.. (1994). Blockers of ATP sensitive potassium current are of potential benefit in ischaemic heart disease. Cardiovascular Research. 28(1). 31–32. 14 indexed citations

10.

Chang, Linda, Wallace T. Ashton, Stacey O’Malley, et al.. (1994). Triazolinone Biphenylsulfonamides as Angiotensin II Receptor Antagonists with High Affinity for Both the AT1 and AT2 Subtypes. Journal of Medicinal Chemistry. 37(26). 4464–4478. 38 indexed citations

11.

Francis, Barbara, et al.. (1993). Antithrombotic activity of recombinant tick anticoagulant peptide and heparin in a rabbit model of venous thrombosis. Thrombosis Research. 71(4). 317–324. 21 indexed citations

12.

Bagley, Scott W., Raymond S.L. Chang, Victor J. Lotti, et al.. (1993). Non-peptide angiotensin II receptor antagonists. 1. Design, synthesis, and biological activity of N-substituted indoles and dihydroindoles. Journal of Medicinal Chemistry. 36(26). 4230–4238. 24 indexed citations

13.

Ashton, Wallace T., et al.. (1992). Inhibitors of human renin with C-termini derived from amides and esters of .alpha.-mercaptoalkanoic acids. Journal of Medicinal Chemistry. 35(15). 2772–2781. 11 indexed citations

14.

Williams, Peter D., Debra S. Perlow, Linda S. Payne, et al.. (1991). Renin inhibitors containing conformationally restricted P1-P1' dipeptide mimetics. Journal of Medicinal Chemistry. 34(3). 887–900. 31 indexed citations

15.

Weber, Ann E., Thomas A. Halgren, John Doyle, et al.. (1991). Design and synthesis of P2-P1'-linked macrocyclic human renin inhibitors. Journal of Medicinal Chemistry. 34(9). 2692–2701. 40 indexed citations

16.

Sanguinetti, Michael C., Nancy K. Jurkiewicz, Alexander P. Scott, & Peter K. S. Siegl. (1991). Isoproterenol antagonizes prolongation of refractory period by the class III antiarrhythmic agent E-4031 in guinea pig myocytes. Mechanism of action.. Circulation Research. 68(1). 77–84. 242 indexed citations

17.

Aharony, David, et al.. (1991). Leukotriene D4 increases both the force of contraction and polyphosphoinositide formation in guinea-pig papillary muscle. European Journal of Pharmacology. 204(2). 223–226. 3 indexed citations

18.

Nutt, Elka M., Deepak Kumar Jain, A. B. Lenny, et al.. (1991). Purification and characterization of recombinant antistasin: A leech-derived inhibitor of coagulation factor Xa. Archives of Biochemistry and Biophysics. 285(1). 37–44. 52 indexed citations

19.

McGrew, Susan G., et al.. (1989). Positive cooperativity of ryanodine binding to the calcium release channel of sarcoplasmic reticulum from heart and skeletal muscle. Biochemistry. 28(4). 1686–1691. 90 indexed citations

20.

Siegl, Peter K. S., et al.. (1988). Interactions of DPI 201-106, a novel cardiotonic agent, with cardiac calcium channels. Naunyn-Schmiedeberg s Archives of Pharmacology. 338(6). 684–691. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact